The Technical Analyst
Select Language :
Midatech Pharma PLC [MTP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Midatech Pharma PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals

Midatech Pharma PLC is listed at the  Exchange

-18.50% $0.285

America/New_York / 24 mar 2023 @ 15:59


Midatech Pharma PLC: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 1.977 mill
EPS: -2.06
P/E: -0.138
Earnings Date: Apr 25, 2023
SharesOutstanding: 6.93 mill
Avg Daily Volume: 1.839 mill
RATING 2023-05-26
B+
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Sell
P/E: Buy
Price To Book: Sell
QUARTER GROWTHS
2/214/212/224/224/222/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebitn/an/an/an/an/an/a
Asset n/an/an/an/a
Debtn/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.138 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.02x
Company: PE -0.138 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 0.0766 - 0.187

( +/- 41.79%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2011-05-10 Kiley Quinn Thomas Buy 1 000 MLP & Strategic Equity Fund
2010-10-06 Zimmerman Gifford R Buy 0
2010-10-06 Toth Terence J Buy 0
2010-10-06 Schneider William J Buy 0
2010-10-06 Martin Larry W Buy 0
INSIDER POWER
0.00
Last 1 transactions
Buy: 1 000 | Sell: 0

Forecast: 01:40 - $0.0980

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.285 (-18.50% )
Volume 0.164 mill
Avg. Vol. 1.839 mill
% of Avg. Vol 8.94 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Midatech Pharma PLC

Last 12 Months

Last 12 months chart data with high, low, open and close for Midatech Pharma PLC

RSI

Intraday RSI14 chart for Midatech Pharma PLC

Last 10 Buy & Sell Signals For MTP

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Midatech Pharma PLC

MTP

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Last 10 Buy Signals

Date Signal @
AGLDUSDMar 29 - 09:301.650
MINAUSDMar 29 - 09:29$1.238
CBKUSDMar 29 - 09:281.087
METAMar 28 - 16:00$485.58
MSTRMar 28 - 16:00$1 704.56
STORJUSDMar 29 - 09:26$0.817
WNEARUSDMar 29 - 09:237.06
BIFIUSDMar 29 - 09:18438.25
MSOLUSDMar 29 - 09:18218.45
DPXUSDMar 29 - 09:1942.00

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.